Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Fresenius H1 2026 Q2 Earnings Call - Guidance Upgraded to 10-15% Core EPS Growth as Biopharma Scales and Cash Generation Accelerates
Fresenius is no longer asking the market to believe in a turnaround. The H1 2026 numbers prove it is already running. Core EPS jumped 14% at constant currency, group margins expanded by 60 basis point...
- Full-year core EPS guidance raised to 10-15% at constant currency, up from 5-10%, reflecting broad-based operational strength and improved earnings quality.
- Biopharma is the primary growth engine, posting 38% organic revenue growth in Q2 and scaling rapidly toward a 20% EBIT margin target by 2030.
- Group EBIT margin expanded 60 basis points to 12.3%, driven by operating leverage across Kabi and Helios without reliance on one-time items.
- +9 more takeaways
Acacia Research Corporation Q2 2026 Earnings Call - Fortress Balance Sheet and Episodic IP Licensing Drive Execution Amid Surging Private Equity Deal Flow
Acacia Research delivered a quarter defined by cash generation and strategic patience rather than linear earnings growth. Total revenue nearly doubled to $114.6 million, largely propelled by a single ...
- Acacia reported total revenue of $114.6 million in Q2 2026, nearly doubling the prior year, driven by a major Wi-Fi 6 licensing settlement.
- Operated segment adjusted EBITDA reached $22.8 million, while total company adjusted EBITDA came in at $17.3 million.
- The company maintains a fortress balance sheet with $334.6 million in cash, securities, and loans receivable and zero parent-level debt.
- +8 more takeaways
Geron Corporation Q2 2026 Earnings Call - RYTELO Revenue Grows 17% as Geron Targets Mid-to-High Full-Year Guidance
Geron Corporation delivered a quarter defined by commercial momentum and financial discipline. RYTELO net revenue climbed 17% to $57.5 million, driven by a third straight quarter of demand growth and ...
- RYTELO net revenue reached $57.5 million in Q2, marking a 17% year-over-year increase and the third consecutive quarter of demand expansion.
- Management projects full-year 2026 RYTELO net revenue to land at the mid-to-high end of the $220 million to $240 million guidance range.
- Operational leverage is evident. First-half operating expenses fell 4% while revenue surged 24%, underscoring the impact of the late-2025 workforce reduction.
- +8 more takeaways
"Aurora Cannabis Inc." Q1 Fiscal 2027 Earnings Call - International Medical Revenue Surges 17% as Global Strategy Offsets Canadian Headwinds
Aurora Cannabis is executing a disciplined pivot that is already reshaping its revenue mix. A 30% cut in Canadian federal reimbursement rates created expected near-term pressure, but the company’s str...
- International medical cannabis net revenue climbed 17% to CAD 43 million, now representing 64% of total net revenue, up from 50% a year ago.
- Consolidated adjusted gross margin held at 58%, landing at the high end of full-year guidance despite expected Canadian reimbursement cuts.
- The Safari Flower Company acquisition is already accretive to adjusted EBITDA and delivers critical EU GMP-certified indoor cultivation capacity.
- +9 more takeaways
"DHL Group" Q2 2026 Earnings Call - Guidance Raised as Express Industrial Pivot Drives Broad Margin Expansion
DHL Group did not just ride the recovery cycle. It engineered it. Revenue accelerated 13% year-over-year while EBIT jumped 30%, a flow-through that leaves management comfortable enough to lift full-ye...
- Group revenue accelerated 13% year-over-year, with EBIT surging 30% as volume growth flowed through the bottom line.
- Management raised full-year guidance, now projecting EBIT to exceed €6.5 billion, backed by broad-based demand recovery.
- The share buyback program extends through 2027 and expands to €6.5 billion in cumulative value, signaling strong confidence in cash generation.
- +8 more takeaways
Gilead Sciences Q2 2026 Earnings Call - Base Business Surges 10% as HIV PrEP Crosses $1B and M&A Charges Compress Reported Margins
Gilead delivered its strongest second quarter growth in three years, with base business sales climbing 10 percent year over year to $7.6 billion. The engine is unmistakably virology. HIV treatment rem...
- Base business sales surged 10 percent year over year to $7.6 billion, with sequential growth of 12 percent driven by strength across HIV, oncology, and liver disease.
- HIV franchise guidance raised to 9 to 10 percent full year growth, up from 8 percent, as Biktarvy maintains treatment leadership and PrEP run rates accelerate.
- PrEP sales exceeded $1 billion quarterly for the first time, establishing a $4 billion annual run rate and validating Gilead's long acting prevention strategy.
- +7 more takeaways
"LeMaitre Vascular" Q2 2026 Earnings Call - Artegraft Growth Offsets Supply and Currency Headwinds
LeMaitre Vascular delivered a quarter defined by structural acceleration and familiar execution friction. Artegraft continues to rewrite the company’s growth curve, jumping 34% and now representing ov...
- Q2 organic revenue growth came in at 10%, driven by 7% pricing and 3% unit growth, though excluding a catheter recall hangover, underlying growth accelerated to 12%.
- Artegraft remains the primary growth engine, surging 34% to capture 21% of total sales, with full-year 2026 sales now forecast at $11 million versus $4 million in 2025.
- The company missed Q2 sales guidance by $1.1 million, split evenly across currency headwinds, Middle East export delays, and cardiac allograft supply bottlenecks.
- +9 more takeaways
"ACADIA Pharmaceuticals" Q2 2026 Earnings Call - DAYBUE STIX Uptake Drives Raised Guidance as Remlifanserin Readout Looms
ACADIA delivered a quarter defined by commercial momentum and pipeline precision. Total revenue climbed 17% to $308 million, anchored by a 30% surge in DAYBUE sales as the new STIX formulation capture...
- Total Q2 revenue reached $308 million, up 17% year-over-year on an adjusted basis, driven by strong volume across both core brands.
- DAYBUE net sales surged 30% to $125 million, fueled by rapid adoption of the STIX formulation, which now accounts for roughly 40% of the U.S. patient base.
- Management raised full-year 2026 DAYBUE guidance to $480 million–$510 million, citing accelerating demand and successful expansion beyond Centers of Excellence.
- +7 more takeaways
Alight Q2 2026 Earnings Call - Management Targets 2028 for Turnaround While Preserving Capital Flexibility
Alight delivered a Q2 2026 print that highlights a familiar services sector friction: commercial improvements take time to hit the bottom line. Revenue fell 3% to $511 million, dragged down by a 4.3% ...
- Q2 revenue landed at $511 million, down 3% year-over-year, with recurring income slipping 4.3% as the company absorbs the lag from prior commercial execution.
- Adjusted EBITDA reached $92 million on an 18% margin, beating street estimates thanks to unexpected project revenue strength and higher operating volumes.
- Full-year 2026 revenue guidance sits between $2.078 billion and $2.098 billion, with adjusted EBITDA projected at $400 million to $415 million.
- +7 more takeaways
Transcat, Inc. Q1 FY2027 Earnings Call - Service Revenue Hits 69th Consecutive Quarter of Growth as New CEO Bets on Operational Excellence
Transcat delivered another quarter of relentless top-line expansion, with consolidated revenue jumping 22% to $92.9 million and service revenue climbing 27%. The 69th straight year-over-year service g...
- Consolidated revenue increased 22% year-over-year to $92.9 million, driven by double-digit growth across both service and distribution segments.
- Service revenue surged 27%, with 13% organic growth marking the company’s 69th consecutive quarter of year-over-year service revenue expansion.
- Service gross profit climbed 31%, with service adjusted operating margins expanding 90 basis points to 15.4%, reflecting inherent operating leverage and maturing customer relationships.
- +8 more takeaways